Commentary: Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer.

Liver cancer is a leading cause of cancer-related deaths worldwide. Early diagnosis and effective and any inaccuracies in this step will inevitably lead to errors in the results.The second question is that in the TMB results analysis, the original text mentions that the overall 25 survival time of the high TMB group is higher than that of the low TMB group, but the results shown 26 in Figure 6B (1) are exactly the opposite. This discrepancy raises questions about the validity of the 27 conclusions drawn from the TMB analysis. Furthermore, the lack of a clear explanation for this 28 discrepancy in the paper makes it difficult for readers to fully understand the implications of these 29 results. Therefore, its conclusions are partially misleading.The third question is about drug sensitivity. The R package used in this paper is pRRophetic (2), 31 which compares its own dataset's drug information, but it has not been updated since 2017, and the it is important to use the latest tools and resources to ensure the most accurate predictions.36 Therefore, if oncoPredict is used for drug prediction, the results should be more accurate.